Table 1.
Highlights of clinical trial survey showcasing the progress of CNS-drug delivery approaches.
| Study Purpose | Year a | Phase | Ref. | |
|---|---|---|---|---|
| 1. | Evaluation of delivery of anti-Aβ with the aid of MA-FUS in patients with AD | 2017 | Phase I/II | [149] |
| 2. | Evaluating the safety and preliminary efficacy of Onivyde® (a nanoliposomal irinotecan) administered in combination with temozolomide in the treatment of patients with recurrent glioblastoma | 2017 | Phase I/II | [150] |
| 3. | Evaluating the safety and efficacy of spherical nucleic acid-conjugated gold nanoparticles (NU-0129) at the treatment of patients with recurrent glioblastoma multiforme or gliosarcoma | 2017 | Early Phase I | [151] |
| 4. | Evaluating brain uptake of temozolomide pre and post transient BBB disruption mediated by administration of regadenoson, a vasoactive peptide, in recurrent high-grade glioma patients | 2015 | Early Phase I | [152] |
| 5. | Evaluating brain uptake of chemotherapeutics upon transient BBB disruption mediated by MRI-guided laser ablation in pediatric patients with brain tumors | 2015 | Phase I | [153,154] |
| 6. | Evaluating brain uptake and efficacy of Pembrolizumab, an anticancer MAb, upon transient BBB disruption mediated by MRI-guided laser ablation in patients with recurrent malignant gliomas | 2015 | Phase I/II | [155,156] |
| 7. | Evaluating the efficacy of etirinotecan pegol at CNS disease control in patients with refractory brain metastases and advanced lung cancer or metastatic breast cancer | 2015 | Phase II | [157,158] |
| 8. | Evaluating the effect of deep transcranial magnetic stimulation on the permeability of the BBB in glioblastoma multiform patients | 2014 | Phase II | [159,160] |
| 9. | Evaluating brain uptake and efficacy of SGT-53, a cationic liposome encapsulating a therapeutic genetic material and decorated with anti-HTfR-MAb fragment, at the induction of apoptosis in patients with recurrent glioblastoma when combined with temozolomide | 2014 | Phase II | [161] |
| 10. | Evaluating brain uptake and efficacy of doxorubicin upon transient BBB disruption mediated by MRI-guided laser ablation in patients with recurrent malignant gliomas | 2013 | Phase I | [162] |
| 11. | Evaluating the efficacy of Safinamide in the treatment of patients with PD | 2009 | Phase III | [163,164] |
| 12. | Evaluation of efficacy of rituximab, an anticancer MAb, given together with methotrexate to treat patients with brain lymphoma after its intraventricular administration | 2007 | Phase I | [165,166] |
| 13. | Evaluation of safety, tolerability, pharmacokinetic and BBB permeability of ANG1005 in patients with recurrent or progressive malignant glioma | 2007 | Phase I/II | [167,168,169,170,171] |
| 14. | Dose optimization of melphalan given together with carboplatin and etoposide phosphate to treat patients with anaplastic oligodendroglioma or oligoastrocytoma after transient BBB disruption mediated by administration of mannitol | 2005 | Phase I/II | [172,173,174] |
| 15. | Evaluation of side effects of methotrexate, rituximab, and carboplatin, given together to treat patients with primary CNS lymphoma after transient BBB disruption mediated by administration of mannitol | 2005 | Phase I/II | [175] |
| 16. | Evaluating the effect of combination therapy of Doxil® and temozolomide in addition to radiotherapy in patients diagnosed with glioblastoma | 2002 | Phase I/II | [176,177] |
| 17. | Side effect evaluation and dose optimization of melphalan administered to treat patients with brain malignancies after transient BBB disruption mediated by administration of mannitol | 1998 | Phase I | [178] |
a Clinical trial starting date was chosen considering that most of the trials listed are not yet completed.